National Kidney Foundation Honors Otsuka Pharmaceutical Company, Ltd., With SCM19 Corporate Innovator Award

Otsuka Pharmaceutical Company, Ltd. has been selected to receive the 2019 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2019 Spring Clinical Meetings in Boston. In April 2018, Otsuka’s JYNARQUETM (tolvaptan) was approved by the U.S. Food and Drug Administration (FDA) as the first treatment to slow kidney function decline in adults at risk of rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD).

ADPKD is diagnosed in about 140,000 people in the U.S., and impacts families across multiple generations, since a parent with ADPKD has a 50 percent chance of passing the disease . . .